SAGE Therapeutics' Series A Round

SAGE Therapeutics raised a round of funding on October 18, 2011. Investors include Third Rock Ventures.

SAGE Therapeutics is a neuroscience-focused company developing medicines to treat rare and orphan diseases of the central nervous system (CNS). SAGE's lead program, SAGE-547, is in clinical developmen…

Articles about SAGE Therapeutics' Series A Round: